Differential effect of CGS 13080, a thromboxane synthase inhibitor, in suppressing serum and urine immunoreactive thromboxane B2 in kidney transplant patients

M. L. Foegh, K. Lim, F. Douglas, J. Turk, G. B. Helfrich, S. A. Taher, M. R. Alijani

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

In this report we describe dose-ranging studies in kidney transplant patients to determine the dose of CGS 13080 that suppress thromboxane during periods of rejection. Formation of TXA2 was identified by urine immunoreactive TXB2 (i-TXB2), which measures both the immediate breakdown product TXB2 and the major urinary metabolite 2,3-dinor-TXB2. Serum TXB2 is a measurement of platelet TXA2 synthesis. In conclusion, 17 kidney transplant patients received seven days' continuous infusion of the TXA2 synthase inhibitor CGS 13080 after an increase in urine i-TXB2 levels. The doses of CGS 13080 varied between 0.04 and 0.50 mg/kg/h, and in all patients serum and urine i-TXB2 accumulations were inhibited. The highest dose was required to maintain inhibition of the urine i-TXB2 content. Finally, the lack of an effect of CGS 13080 on bleeding time in these patients contrasts with the elevated bleeding time observed in volunteers after a single oral dose. These data encourage more extensive evaluation of CGS 13080 and thromboxane synthase inhibitors for treating renal transplant patients.

Original languageEnglish
Pages (from-to)424-427
Number of pages4
JournalTransplantation Proceedings
Volume20
Issue number1 SUPPL. 1
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint Dive into the research topics of 'Differential effect of CGS 13080, a thromboxane synthase inhibitor, in suppressing serum and urine immunoreactive thromboxane B<sub>2</sub> in kidney transplant patients'. Together they form a unique fingerprint.

  • Cite this